2004; 34(2):336-44. Heat Biologics, Inc. Investigational Product: V iagenpumatucel -L Protocol HS110 -201 CONFIDENTIAL Version 4.0; 29 -Oct-2014 Page 84 of 84 62 Cytoxan Prescribing Information: http://packageinserts.bms.com/pi/pi_cytoxan.pdf 63 Emmenegger U et al. A Comparative Analysis of Low -Dose Metronomic Cyclophosphamide Reveals Absent or Low -Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Ma ximum Tolerated Dose Regimens. Cancer Res 2004;64:3994 -4000. 64 Lien K et al Low-dose metronomic chemotherapy: A systematic literature analysis . European Journal of Cancer, 2013; 49: 3387=3395 65 Penel N et al. Cyclophosphamide -based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? Critical Re views in Oncology/Hematology, 2012; 82: 40–50 66 Mross K et al. Journal of Cancer Therapeutics & Research 2012, http://www.hoajonline.com/journals/pdf/2049 -7962 -1-32.pdf 67 Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune -related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412 -20. 68 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228 -47. 69 Fine GD. Consequences of Delayed Treatment Effects on Analysis of Time -to-Event Endpoints. Drug Information Journal 2007;41:535 -39. 70 George SL. Identification and assessment of prognostic factors. Semin Oncol 1988;15:46 2-71. 71 Royston P, Parmar MK. The use of restricted mea n survival time to estimate the treatment effect in randomized clinical trial s when the proportional hazards assumption is in doubt. Stat Med. 2011 Aug 30;30(19):2409 -21. 72 Chen TT. Statistical issues and challenges in immune -oncology. J Immunother Can 2013;1:2 -9. 73 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649 - 655.